Chelsea Therapeutics’ Northera Advisory Review May Turn On Validity Of Combined Clinical Trial Analysis
This article was originally published in The Pink Sheet Daily
Only one of two pivotal Phase III clinical trials of Chelsea Therapeutics’ Northera (droxidopa) for symptomatic neurogenic orthostatic hypotension showed significant results, but a combined analysis of both trials ascribes major improvement on three separate scores for subjects in the active arm.
You may also be interested in...
Not The Next Avastin? Plan For New ProAmatine Studies Would Negate Shire’s Withdrawal Hearing Request
A joint proposal from CDER and Shire calling for two new studies to verify clinical benefit of the hypotension agent would negate the need for a hearing on CDER’s proposed withdrawal, if Commissioner Hamburg accepts it.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.